Extensive-stage small-cell lung cancer ( SCLC ) patients who progress after platinum-based chemotherapy are traditionally categorized as platinum sensitive ( progression 90 days from last platinum dose ) or refractory ( progression < 90 days ) , a practice arising from seminal observations of worse survival in refractory patients .